Thursday, 15 October 2026European Markets

MEDIA 6 Stock Went Up By Over 32% In The Last 21 Sessions

Loading stream...

(vianews) - shares of media 6 (cac 40: edi.pa) rose by a staggering 32.45% in 21 sessions from €7.55 to €10.00 at 14:06 est on friday, following the last session's upward trend. cac 40 is jumping 0.7% to €7,433.49, following the last session's upward trend.

media 6's last close was €10.00, 9.91% below its 52-week high of €11.10.

about media 6

groupe media 6, a point-of-purchase (pop) advertising company, provides multi-material solutions in france and internationally. the company offers hydro-alcoholic gel dispensing column with pmr access options, counter displays, plexiglass protective barriers, protective visors, and floor markings; merchandising management services; point-of-purchase marketing; installs furniture, shop windows, podiums, and communication materials; and processes cardboard, wood, metal, and plastic products. it also provides experiential marketing, pop displays, shop fixtures, shop fittings, pharmacy fittings, trade marketing, and pop display for coloration, as well as operates art workshop. in addition, it offers various tools for the customization of sales accessories, product racks, bag and shoe doors, presentation trays, articulated hands, wooden feet and head, and busts and displays for shops. the company was founded in 1977 and is based in tremblay-en-france, france. groupe media 6 is a subsidiary of vasco sarl.

earnings per share

as for profitability, media 6 has a trailing twelve months eps of €0.18.

pe ratio

media 6 has a trailing twelve months price to earnings ratio of 55.56. meaning, the purchaser of the share is investing €55.56 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.87%.

more news about media 6 (edi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com